19 December 2024
19 December 2024
Catalent common stock holders are set to obtain $63.50 per share in cash.
A new report identifies data content management as the primary driver of growth in the pharmaceuticals market.
BioAge will receive an upfront payment and research funding of up to $20m.
New hope for long-COVID patients: Longidaza boosts exercise tolerance and improves pulmonary function.
The main funding source for the partnership is the Coalition for Epidemic Preparedness Innovations.
Healthcare companies are starting to integrate new strategies to reduce their emissions caused by industrial refrigeration.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
